Inlyta

Axitinib, the active ingredient in Inlyta, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats advanced or metastatic renal cell carcinoma, typically after prior systemic therapy.

GNH USA supplies Inlyta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Inlyta (axitinib) is indicated for cancers that depend on vascular endothelial growth factor signaling.

Metastatic renal cell carcinoma: improves progression‑free survival after prior systemic therapy Advanced renal cell carcinoma: used when disease has progressed following first‑line treatment Kidney cancer (clear‑cell): indicated for patients with progressive disease after earlier therapy

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring - Diarrhea: watery stools that may lead to dehydration - Fatigue: persistent tiredness affecting daily activities - Nausea: feeling of sickness often accompanied by loss of appetite - Decreased appetite: reduced desire to eat, potentially causing weight loss - Hand‑foot syndrome: redness or swelling of palms and soles

Serious or Rare Side Effects: - Arterial thromboembolism: risk of heart attack or stroke - Gastrointestinal perforation: possible tearing of the stomach or intestines - Severe hemorrhage: uncontrolled bleeding in various organs - Hepatic failure: serious liver injury with elevated enzymes

Patients receiving Inlyta should be monitored closely for cardiovascular and hepatic safety.

Blood pressure monitoring: check regularly due to risk of hypertension Cardiovascular assessment: evaluate for history of arterial events before starting therapy Liver function tests: monitor for hepatic toxicity during treatment Bleeding risk: assess before surgery or when using anticoagulants Pregnancy and lactation: avoid use; discuss risks with physician Store at ambient temperature: keep below 25°C in original container, protect from moisture

Axitinib may interact with several medications; careful review is advised.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase axitinib exposure - Potent CYP3A4 inducers (e.g., rifampin): may reduce efficacy - Anticoagulants (e.g., warfarin): increased bleeding risk

Moderate Interactions (Monitor Closely): - Antihypertensives: may require dose adjustment due to additive blood‑pressure effects - Diuretics: monitor electrolytes and renal function - Other VEGF inhibitors: additive toxicity, especially hypertension and proteinuria